{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T01:56:18Z","timestamp":1780624578331,"version":"3.54.1"},"reference-count":18,"publisher":"Japanese Society of Internal Medicine","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2022,5,1]]},"DOI":"10.2169\/internalmedicine.7622-21","type":"journal-article","created":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T23:24:07Z","timestamp":1634599447000},"page":"1457-1461","source":"Crossref","is-referenced-by-count":4,"title":["Successful Treatment of Symptomatic Epilepsy with Oral Valproic Acid and Levetiracetam in a Patient with Short-bowel Syndrome"],"prefix":"10.2169","volume":"61","author":[{"given":"Akira","family":"Kurishima","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Japan Community Health Care Organization Tokyo Shinjuku Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mototaka","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Neuroendovascular Therapy, Japan Community Health Care Organization Tokyo Shinjuku Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rin","family":"Shimozato","sequence":"additional","affiliation":[{"name":"Department of Neuroendovascular Therapy, Japan Community Health Care Organization Tokyo Shinjuku Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Isozaki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Japan Community Health Care Organization Tokyo Shinjuku Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Shioda","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Japan Community Health Care Organization Tokyo Shinjuku Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Iijima","sequence":"additional","affiliation":[{"name":"Department of Neuroendovascular Therapy, Japan Community Health Care Organization Tokyo Shinjuku Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Severijnen R, Bayat N, Bakker H, Tolboom J, Bongaerts G. Enteral drug absorption in patients with short small bowel: a review. Clin Pharmacokinet 43: 951-962, 2004.","DOI":"10.2165\/00003088-200443140-00001"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Felser J, Hui KK. Procainamide absorption in short bowel syndrome. JPEN J Parenter Enteral Nutr 7: 154-155, 1983.","DOI":"10.1177\/0148607183007002154"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Ikuma M, Watanabe D, Yagura H, et al. Therapeutic drug monitoring of anti-human immunodeficiency virus drugs in a patient with short bowel syndrome. Intern Med 55: 3059-3063, 2016.","DOI":"10.2169\/internalmedicine.55.6777"},{"key":"4","unstructured":"4. Japanese Society of Neurology. Clinical Guideline for Epilepsy Management 2018. 1st ed. Igaku Shoin, Tokyo, 2018: 153-162."},{"key":"5","unstructured":"5. Japanese Society of Neurology. Clinical Guideline for Epilepsy Management 2018. 1st ed. Igaku Shoin, Tokyo, 2018: 25-38."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Yeomans ND, Vajda FJ, Baldas J. Bioavailability of valproate after gastric and direct intestinal administration in rats. Clin Exp Pharmacol Physiol 9: 173-177, 1982.","DOI":"10.1111\/j.1440-1681.1982.tb00794.x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Nahata MC, Breech L, Ailabouni A, Murray RD. Absorption of valproic acid from the gastrointestinal tract of the piglet. Eur J Drug Metab Pharmacokinet 17: 129-134, 1992.","DOI":"10.1007\/BF03188781"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Stockis A, Sargentini-Maier ML, Otoul C, Connor A, Wilding I, Wray H. Assessment of levetiracetam bioavailability from targeted sites in the human intestine using remotely activated capsules and gamma scintigraphy: open-label, single-dose, randomized, four-way crossover study in healthy male volunteers. Clin Ther 32: 1813-1821, 2010.","DOI":"10.1016\/j.clinthera.2010.09.001"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Schiefecker AJ, Beer R, Steidl J, et al. Refractory status epilepticus in a patient with short bowel syndrome--a microdialysis study. Seizure 22: 236-239, 2013.","DOI":"10.1016\/j.seizure.2012.11.016"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. May TW, Rambeck B, J\u00fcrgens U. Serum concentrations of levetiracetam in epileptic patients: the influence of dose and co-medication. Ther Drug Monit 25: 690-699, 2003.","DOI":"10.1097\/00007691-200312000-00007"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 49: 1239-1276, 2008.","DOI":"10.1111\/j.1528-1167.2008.01561.x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Verrotti A, Prezioso G, Di Sabatino F, Franco V, Chiarelli F, Zaccara G. The adverse event profile of levetiracetam: a meta-analysis on children and adults. Seizure 31: 49-55, 2015.","DOI":"10.1016\/j.seizure.2015.07.004"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kang BS, Moon HJ, Kim YS, et al. The long-term efficacy and safety of levetiracetam in a tertiary epilepsy centre. Epileptic Disord 15: 302-310, 2013.","DOI":"10.1684\/epd.2013.0599"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. May TW, Rambeck B, J\u00fcrgens U. Serum concentrations of levetiracetam in epileptic patients: the influence of dose and co-medication. Ther Drug Monit 25: 690-699, 2003.","DOI":"10.1097\/00007691-200312000-00007"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Alzueta N, Ortega A, Aldaz A. Influence of sex, age, and weight on levetiracetam pharmacokinetics. Ther Drug Monit 40: 628-634, 2018.","DOI":"10.1097\/FTD.0000000000000550"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Nahata MC, Freimer N, Hilty MD. Decreased absorption of cefaclor in short bowel syndrome. Drug Intell Clin Pharm 17: 201-202, 1983.","DOI":"10.1177\/106002808301700307"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Backman L, Beerman B, Groschinsky-Grind M, Hallberg D. Malabsorption of hydrochlorothiazide following intestinal shunt surgery. Clin Pharmacokinet 4: 63-68, 1979.","DOI":"10.2165\/00003088-197904010-00006"},{"key":"18","unstructured":"18. The Japanese Society of Therapeutic Drug Monitoring. Antiepileptic Drugs TDM Standardization Guidelines 2018. 1st ed. Kinbara Press, Tokyo, 2018: 25-38."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/9\/61_7622-21\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,7]],"date-time":"2022-05-07T03:32:37Z","timestamp":1651894357000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/9\/61_7622-21\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,1]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7622-21","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,1]]},"article-number":"7622-21"}}